miR-766-3p通过抑制NR3C2促进非小细胞肺癌的发展
Xuexi Zhang1, Lei Cao2, Gang Zhang1
1Department of Thoracic Surgery, Linyi People's Hospital, Linyi, Shandong, China.
Nucleosides, nucleotides & nucleic acids
|July 20, 2025
概括
微RNA-766-3p (miR-766-3p) 在非小细胞肺癌 (NSCLC) 组织中升高,与预后不佳有关. 这种微RNA通过抑制NR3C2促进NSCLC,表明它是潜在的治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 全球非小细胞肺癌 (NSCLC) 发病率正在上升,这对健康构成重大威胁.
- 驱动NSCLC进展的潜在分子机制仍然不完全理解.
- 识别新的生物标志物和治疗点对于改善患者的治疗结果至关重要.
研究的目的:
- 研究miR-766-3p在NSCLC组织中的表达水平和预后意义.
- 在NSCLC中探索miR-766-3p与核受体亚家族3组C成员2 (NR3C2) 之间的关系.
- 阐明miR-766-3p在NSCLC细胞增殖,迁移和入侵中的作用.
主要方法:
- 定量实时聚合酶连锁反应 (RT-qPCR) 用于测量miR-766-3p和NR3C2的表达.
- 卡普兰-梅尔和考克斯对生存分析的比例危险模型.
- 在体外测定包括CCK-8,流动细胞计,Transwell迁移/入侵,以及 luciferase 记者测定.
主要成果:
- 与对照组相比,miR-766-3p表达在NSCLC瘤组织中显著上调.
- 高的miR-766-3p水平与NSCLC患者的预后不佳相关.
- 在NSCLC血清中,NR3C2表达被下调,miR-766-3p过度表达促进NSCLC细胞增殖和转移,部分是通过抑制NR3C2.2.
结论:
- miR-766-3p通过抑制NR3C2,从而促进瘤发育,在NSCLC中起到瘤性微RNA的作用.
- miR-766-3p是NSCLC的潜在诊断生物标志物和治疗点.
- 升高的miR-766-3p水平可能预测NSCLC患者的临床结果不佳.
相关概念视频
MicroRNAs
3.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K


